EMA grants marketing authorisation for subcutaneous formulation of Benlysta against lupus
The EU has approved a new subcutaneous formulation of Benlysta,…
The EU has approved a new subcutaneous formulation of Benlysta, as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus...